Why it issues: Genetic testing firm 23andMe, has introduced a dramatic restructuring, together with 200 job cuts and the discontinuation of its therapeutics division. This transfer comes after a devastating 12 months marked by a serious data breach and plummeting inventory worth.
The Cuts: The BBC reviews that the corporate will scale back its workforce by 40%, anticipating to save lots of $35 million yearly whereas incurring $12 million in severance and transition prices. The restructuring contains abandoning cancer-treatment analysis packages as the corporate refocuses on its core client enterprise.
- 200 positions eradicated (Gizmodo)
- Analysis packages discontinued
Anne Wojcicki, 23andMe’s CEO and co-founder: “We’re taking these troublesome however crucial actions as we restructure 23andMe and give attention to the long-term success of our core client enterprise and analysis partnerships,” mentioned Wojcicki in a press release. “I need to thank our group for his or her onerous work and dedication to our mission. We’re absolutely dedicated to supporting the staff impacted by this transition.”
Monetary Strain: Since going public in 2021 with a $3.5 billion valuation, 23andMe has confronted mounting challenges. The corporate reported a $59.1 million web loss in its newest quarter, whereas its inventory has dropped over 70% this 12 months, buying and selling beneath $5.
- Vital quarterly losses
- Inventory worth plummets
Safety Considerations: A 2023 information breach uncovered the non-public data of 6.9 million customers, together with household bushes and geographic areas, although DNA data remained safe. This incident has additional eroded client confidence and firm worth. Customers must learn to shield their DNA data.
About The Author
